Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab

Catherine Lai, Vishal Ranpura,Colin Wu,Matthew J. Olnes,Ankur R. Parikh,Aarthi Shenoy,Julie Thompson,Barbara Weinstein,Phillip Scheinberg,A. John Barrett,Ronan Desmond,Neal S. Young,Christopher S. Hourigan

Blood Advances（2019）

引用 7|浏览28

暂无评分

摘要

TO THE EDITOR:Treatment of myelodysplastic syndrome (MDS) is suboptimal. Responses to hematopoietic growth factors, hypomethylating agents, and lenalidomide in 5q− syndromes are not sustained, and not all patients benefit. Allogeneic stem cell transplantation is potentially curative but only

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要